Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax is poised for long-term success due to its strong pipeline of vaccine candidates targeting a wide range of diseases, backed by its novel vaccine technology and partnerships with major pharmaceutical companies. Recent data from the SNY-led H2H trial and third-party reviews suggest that Nuvaxovid, the company's COVID-19 vaccine candidate, may have a differentiated tolerability profile compared to mRNA vaccines. With positive sales predictions, strong partnerships, and a promising adjuvant technology in Matrix-M, Novavax has the potential for significant growth in the coming years.

Bears say

Novavax is heavily reliant on partnerships for value creation, which may not yield the desired returns and the success of their products hinges on regulatory approvals for which there are potential setbacks. Given the highly competitive nature of the vaccine market and the potential for the SARS-CoV-2 virus to be eradicated, the long-term growth outlook for this company may not be sustainable. Financially, the current sales of their COVID-19 vaccine, Nuvaxovid, are insignificant, and the company is still in the early stages of developing their pipeline products and is yet to generate significant revenue.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.